While dual and triple agonists represent a promising area of pharmacologic innovation, their role in adolescent obesity management cannot be established without dedicated pediatric clinical trials
Heres how
Department of Health and Human Services, if you dont already drink, its not recommended that you start
2023;doi:10.3389/fendo.2023.1215356
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists Authors Abid M, Sheikh KS, Ahmad MS, Jiang H Received 19 January 2026 Accepted for publication 17 March 2026 Published 12 June 2026 Volume 2026:19 566414 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Donald McClain Mahroz Abid, 1 Khizer Sohail Sheikh, 1 Muhammad Shahbaz Ahmad, 2 Hongwei Jiang 1 1 Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Peoples Republic of China
Mitochondrial glutamate transporter SLC25A22 uni-directionally export glutamate for metabolic rewiring in radioresistant glioblastoma